1. Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine Published Online First: 22 April 2021. doi: 10.1136/bmjebm-2021-111678
2. BPOM. Penjelasan Badan POM RI tentang informasi penggunaan ivermectin. 2021. https://www.pom.go.id/new/view/more/klarifikasi/136/PENJELASAN-BADAN-POM-RI-Tentang-Informasi-Penggunaan-Ivermectin.html
3. Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol. 2021. PMID: 34076901.
4. National Center for Biotechnology Information. 2021. PubChem Compound. https://pubchem.ncbi.nlm.nih.gov/compound/Ivermectin-B1b.
5. Jans DA, Wagstaff KM. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?. Cells. 2020;9(9):2100.
6. Wang X, Lv C, Ji X, Wang B, Qiu L, Yang Z. Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets. Virus Res. 2019;263:80-86.
7. Caly, L., Druce, J.D., Catton, M.G., Jans, D.A. and Wagstaff, K.M., 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research, 178, p.104787
8. Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, et al. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2021 Jun 28:ciab591. doi: 10.1093/cid/ciab591. Epub ahead of print. PMID: 34181716.
9. Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021. doi: 10.1097/MJT.0000000000001402.
10. Behera P, Patro BK, Singh AK, et al. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS One. 2021;16(2):e0247163.
11. Chandler RE. Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?. Am J Trop Med Hyg. 2018;98(2):382-388.
12. Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. EClinicalMedicine. 2021;37:100959.
13. European Medicines Agency (EMA). EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials. 2021. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials
14. NIH. Ivermectin. 2021. https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/